title: Selection of a highly invasive neuroblastoma cell population through long-term human cytomegalovirus infection.
abstract: The human cytomegalovirus (HCMV) is suspected to increase tumour malignancy by infection of cancer and/or stroma cells (oncomodulation). So far, oncomodulatory mechanisms have been attributed to the presence of HCMV and direct action of its gene products on cancer cells. Here, we investigated whether the prolonged presence of HCMV can result in the irreversible selection of a cancer cell population with increased malignancy. The neuroblastoma cell line UKF-NB-4 was long-term (200 passages) infected with the HCMV strain Hi91 (UKF-NB-4(Hi)) before virus eradication using ganciclovir (UKF-NB-4(HiGCV)). Global gene expression profiling of UKF-NB-4, UKF-NB-4(Hi) and UKF-NB-4(HiGCV) cells and subsequent bioinformatic signal transduction pathway analysis revealed clear differences between UKF-NB-4 and UKF-NB-4(Hi), as well as between UKF-NB-4 and UKF-NB-4(HiGCV) cells, but only minor differences between UKF-NB-4(Hi) and UKF-NB-4(HiGCV) cells. Investigation of the expression of a subset of five genes in different chronically HCMV-infected cell lines before and after virus eradication suggested that long-term HCMV infection reproducibly causes specific changes. Array comparative genomic hybridisation showed virtually the same genomic differences for the comparisons UKF-NB-4(Hi)/UKF-NB-4 and UKF-NB-4(HiGCV)/UKF-NB-4. UKF-NB-4(Hi) cells are characterised by an increased invasive potential compared with UKF-NB-4 cells. This phenotype was completely retained in UKF-NB-4(HiGCV) cells. Moreover, there was a substantial overlap in the signal transduction pathways that differed significantly between UKF-NB-4(Hi)/UKF-NB-4(HiGCV) and UKF-NB-4 cells and those differentially regulated between tumour tissues from neuroblastoma patients with favourable or poor outcome. In conclusion, we present the first experimental evidence that long-term HCMV infection can result in the selection of tumour cell populations with enhanced malignancy.
authors.affiliation: Institut für Medizinische Virologie, Klinikum der J.W. Goethe-Universität, Frankfurt am main, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Michaelis
authors.forename: S
authors.initials: S
authors.lastname: Barth
authors.forename: R
authors.initials: R
authors.lastname: Breitling
authors.forename: J
authors.initials: J
authors.lastname: Bruch
authors.forename: D
authors.initials: D
authors.lastname: Steinberger
authors.forename: F
authors.initials: F
authors.lastname: Rothweiler
authors.forename: K
authors.initials: K
authors.lastname: Hackmann
authors.forename: E
authors.initials: E
authors.lastname: Schröck
authors.forename: H W
authors.initials: HW
authors.lastname: Doerr
authors.forename: D K
authors.initials: DK
authors.lastname: Griffin
authors.forename: J
authors.initials: J
authors.lastname: Cinatl
authors.forename: J
authors.initials: J
authors.lastname: Cinatl
references.citation: Cancer Res. 1998 Jan 15;58(2):367-72
references.pmid: 9443419
references.citation: Virology. 1984 Aug;137(1):191-4
references.pmid: 6089416
references.citation: Rev Med Virol. 2003 Jan-Feb;13(1):21-37
references.pmid: 12516060
references.citation: J Virol. 2012 Jan;86(2):854-64
references.pmid: 22090104
references.citation: Int J Cancer. 1996 Jan 3;65(1):90-6
references.pmid: 8543403
references.citation: Med Pediatr Oncol. 1995 Mar;24(3):200-3
references.pmid: 7838043
references.citation: J Clin Virol. 2008 Mar;41(3):218-23
references.pmid: 18164235
references.citation: J Neurooncol. 2011 Dec;105(3):451-66
references.pmid: 21720806
references.citation: J Natl Cancer Inst. 2009 Apr 1;101(7):441-3
references.pmid: 19318630
references.citation: Int J Oncol. 1999 Nov;15(5):1001-9
references.pmid: 10536185
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3341-5
references.pmid: 9096395
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17234-9
references.pmid: 15572445
references.citation: J Natl Cancer Inst. 2006 Sep 6;98(17):1193-203
references.pmid: 16954472
references.citation: Med Microbiol Immunol. 2011 Feb;200(1):1-5
references.pmid: 20967552
references.citation: Herpesviridae. 2010 Dec 23;1(1):8
references.pmid: 21429243
references.citation: Nat Rev Cancer. 2011 May;11(5):375-82
references.pmid: 21508974
references.citation: J Natl Cancer Inst. 2009 Apr 1;101(7):488-97
references.pmid: 19318640
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Virus Res. 2011 May;157(2):193-203
references.pmid: 21036194
references.citation: J Immunol. 2001 Aug 15;167(4):1900-8
references.pmid: 11489969
references.citation: Arch Virol. 1994;138(3-4):391-401
references.pmid: 7998845
references.citation: Biochem Biophys Res Commun. 2005 Jan 14;326(2):395-401
references.pmid: 15582591
references.citation: Tissue Antigens. 2000 May;55(5):412-21
references.pmid: 10885561
references.citation: Cell Mol Life Sci. 2011 Mar;68(6):1079-90
references.pmid: 20803231
references.citation: Neoplasia. 2009 Jan;11(1):1-9
references.pmid: 19107226
references.citation: Intervirology. 1996;39(4):259-69
references.pmid: 9078467
references.citation: J Clin Invest. 2010 Nov;120(11):3969-78
references.pmid: 20978345
references.citation: Acta Neuropathol. 2008 Jul;116(1):79-86
references.pmid: 18351367
references.citation: Sci Signal. 2010 Aug 03;3(133):ra58
references.pmid: 20682912
references.citation: J Neuroimmune Pharmacol. 2010 Sep;5(3):387-403
references.pmid: 20387126
references.citation: J Clin Invest. 2011 Oct;121(10):4043-55
references.pmid: 21946257
references.citation: Trends Genet. 2000 Sep;16(9):409-15
references.pmid: 10973070
references.citation: J Virol. 2007 Oct;81(19):10424-36
references.pmid: 17652378
references.citation: Nat Rev Cancer. 2010 Dec;10(12):878-89
references.pmid: 21102637
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73
references.pmid: 16924106
references.citation: J Gen Virol. 1986 Dec;67 ( Pt 12):2605-16
references.pmid: 3025342
references.citation: Curr Top Microbiol Immunol. 2008;325:243-62
references.pmid: 18637510
references.citation: Bioessays. 2003 Jan;25(1):58-65
references.pmid: 12508283
references.citation: Nucleic Acids Res. 2007 Jan;35(Database issue):D247-52
references.pmid: 17130144
references.citation: PLoS Pathog. 2011 Apr;7(4):e1002016
references.pmid: 21533215
references.citation: J Clin Oncol. 2006 Nov 1;24(31):5070-8
references.pmid: 17075126
references.citation: Clin Cancer Res. 2011 Jul 15;17(14):4642-9
references.pmid: 21490182
references.citation: J Natl Cancer Inst. 1976 Sep;57(3):701-3
references.pmid: 185403
references.citation: J Biomed Sci. 2009 Nov 25;16:107
references.pmid: 19930723
references.citation: Stat Appl Genet Mol Biol. 2004;3:Article3
references.pmid: 16646809
references.citation: J Clin Neurosci. 2010 Jul;17(7):819-23
references.pmid: 20427188
references.citation: Nature. 2012 Jan 18;481(7381):306-13
references.pmid: 22258609